1. Home
  2. OSUR vs ACIU Comparison

OSUR vs ACIU Comparison

Compare OSUR & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OraSure Technologies Inc.

OSUR

OraSure Technologies Inc.

HOLD

Current Price

$4.19

Market Cap

275.4M

Sector

Health Care

ML Signal

HOLD

Logo AC Immune SA

ACIU

AC Immune SA

HOLD

Current Price

$2.26

Market Cap

229.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OSUR
ACIU
Founded
2000
2003
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
275.4M
229.0M
IPO Year
2000
2015

Fundamental Metrics

Financial Performance
Metric
OSUR
ACIU
Price
$4.19
$2.26
Analyst Decision
Hold
Strong Buy
Analyst Count
2
2
Target Price
$3.00
$10.00
AVG Volume (30 Days)
818.8K
290.6K
Earning Date
05-06-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$167,064,000.00
N/A
Revenue This Year
$4.48
$706.75
Revenue Next Year
$7.76
$321.13
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.08
$1.65
52 Week High
$4.33
$4.00

Technical Indicators

Market Signals
Indicator
OSUR
ACIU
Relative Strength Index (RSI) 65.34 31.71
Support Level $2.80 $2.03
Resistance Level $4.33 $3.92
Average True Range (ATR) 0.25 0.16
MACD 0.01 -0.05
Stochastic Oscillator 90.87 12.83

Price Performance

Historical Comparison
OSUR
ACIU

About OSUR OraSure Technologies Inc.

OraSure Technologies Inc is principally engaged in the development, manufacture, marketing, sale and distribution of (i) diagnostics products, and (ii) sample management solutions. It develops products and services that support diagnostic testing and healthcare data analysis, with a focus on improving access to healthcare. The company derives its revenues from the sale of diagnostics products and sample management solutions. Geographically, it generates the maximum revenue from the United States.

About ACIU AC Immune SA

AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

Share on Social Networks: